Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, Turkovic B, Rotkvic I, Mise S, Zoricic I, Konjevoda P, Perovic D, Simicevic V, Separovic J, Hanzevacki M, Ljubanovic D, Artukovic B, Bratulic M, Tisljar M, Rekic B, Gjurasin M, Miklic P, Buljat G
Techniques such as 3D bioprinting and scaffold-based approaches aim to create ligament constructs that mimic the native ACLs geometry and mechanical properties
The image below highlights the mechanisms of both GLP-1 and GIP, along with a callout to the newest treatment optiona triple incretin that also includes glucagonexpected to be approved in late 2025 to early 2026
Note the mixing date and store at 28 C (35.646.4 F) , shielded from light
doi: 10.1007/s00125-013-3145-0